Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metaproterenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 14/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaproterenol SCHEMBL3049439 | 1.00 | MEN1 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL6862596 | 1.00 | MEN1 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL41816 | 1.00 | MEN1 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL9614523 | 1.00 | MEN1 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL8330430 | 0.94 | BLM (0.88) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL4271 | 0.91 | ADRB2 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL4270 | 0.91 | ADRB2 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL4451598 | 0.91 | ADRB2 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL3694829 | 0.91 | ADRB2 (1.00) | MEN1LMNABLMKMT2AAPEX1 | |
| Metaproterenol SCHEMBL5682997 | 0.90 | ADRB2 (0.96) | MEN1LMNABLMKMT2AAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6540 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | claimed |
| CN-117070544-B | Light response reversible protein assembly system based on artificial protein cage and construction method thereof | 大连理工大学 | 2024-04-05 | — | — | CN | claimed |
| EP-4259153-A1 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | Voronoi Inc. (KR) | 2023-10-18 | — | — | EP | claimed |
| EP-4255541-A1 | PRODUCT DELIVERY DEVICES AND METHODS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4255390-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230181847-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE INC (US) | 2023-06-15 | — | — | US | claimed |
| US-11672929-B2 | Product delivery devices and methods | BREATHE RESTORE, INC. (US) | 2023-06-13 | — | — | US | claimed |
| EP-4143150-A2 | VIRUS TREATMENT METHODS, AND RELATED PHARMACEUTICAL COMPOSITIONS, VACCINE COMPOSITIONS, SANITIZING COMPOSITIONS, AND DRUG DISCOVERY METHODS | Cashman, Daniel Patrick (US) | 2023-03-08 | — | — | EP | claimed |
| US-20220270733-A1 | SYSTEMS AND METHODS FOR DETERMINING COMPLIANCE AND EFFICACY OF A DOSING REGIMEN FOR A PHARMACEUTICAL AGENT | SUMNER BLUFFS LLC (US) | 2022-08-25 | — | — | US | claimed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | claimed |
| WO-1990006775-A1 | A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS | LIPOSOME TECHNOLOGY, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| EP-0369608-A1 | Gel bases for pharmaceutical compositions | THAMES PHARMACAL CO.INC. (US) | 1990-05-23 | — | — | EP | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0349763-A1 | Compositions for enhancing transdermal penetration | Bristol-Myers Squibb Company (US) | 1990-01-10 | — | — | EP | claimed |
| US-4883660-A | Gel bases for pharmaceutical compositions | THAMES PHARMACAL CO., INC. (US) | 1989-11-28 | — | — | US | claimed |
| EP-0223831-A4 | LIPOSOME INHALATION METHOD AND SYSTEM. | LIPOSOME TECHNOLOGY INC (US) | 1987-10-12 | — | — | EP | claimed |
| EP-0223831-A1 | LIPOSOME INHALATION METHOD AND SYSTEM. | LIPOSOME TECHNOLOGY INC (US) | 1987-06-03 | — | — | EP | claimed |
| WO-1986006959-A1 | LIPOSOME INHALATION METHOD AND SYSTEM | LIPOSOME TECHNOLOGY, INC. (US) | 1986-12-04 | — | — | WO | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |